PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 41 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 2.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,000 | +63.9% | 5,716 | +128.5% | 0.00% | – |
| Q2 2023 | $36,000 | +176.9% | 2,502 | +32.7% | 0.00% | – |
| Q1 2023 | $13,000 | -71.7% | 1,885 | -54.5% | 0.00% | – |
| Q4 2022 | $46,000 | +1433.3% | 4,139 | +1378.2% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 280 | +115.4% | 0.00% | – |
| Q2 2022 | $1,000 | -94.1% | 130 | -89.5% | 0.00% | – |
| Q1 2022 | $17,000 | -80.5% | 1,244 | -72.0% | 0.00% | – |
| Q4 2021 | $87,000 | +45.0% | 4,447 | +138.1% | 0.00% | – |
| Q3 2021 | $60,000 | +27.7% | 1,868 | +34.7% | 0.00% | – |
| Q2 2021 | $47,000 | +88.0% | 1,387 | +109.5% | 0.00% | – |
| Q1 2021 | $25,000 | – | 662 | +9357.1% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 7 | -65.0% | 0.00% | – |
| Q2 2020 | $1,000 | -92.3% | 20 | -96.1% | 0.00% | – |
| Q1 2020 | $13,000 | -40.9% | 514 | -25.8% | 0.00% | – |
| Q4 2019 | $22,000 | – | 693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |